388 related articles for article (PubMed ID: 34814918)
1. Three decades of Cdk5.
Pao PC; Tsai LH
J Biomed Sci; 2021 Nov; 28(1):79. PubMed ID: 34814918
[TBL] [Abstract][Full Text] [Related]
2. Cdk5: multitasking between physiological and pathological conditions.
Lopes JP; Agostinho P
Prog Neurobiol; 2011 Jun; 94(1):49-63. PubMed ID: 21473899
[TBL] [Abstract][Full Text] [Related]
3. Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease.
Allnutt AB; Waters AK; Kesari S; Yenugonda VM
ACS Chem Neurosci; 2020 May; 11(9):1218-1230. PubMed ID: 32286796
[TBL] [Abstract][Full Text] [Related]
4. Cdk5: mediator of neuronal development, death and the response to DNA damage.
Zhu J; Li W; Mao Z
Mech Ageing Dev; 2011 Aug; 132(8-9):389-94. PubMed ID: 21600237
[TBL] [Abstract][Full Text] [Related]
5. CDK5 activator protein p25 preferentially binds and activates GSK3β.
Chow HM; Guo D; Zhou JC; Zhang GY; Li HF; Herrup K; Zhang J
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4887-95. PubMed ID: 25331900
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinases in brain development and disease.
Su SC; Tsai LH
Annu Rev Cell Dev Biol; 2011; 27():465-91. PubMed ID: 21740229
[TBL] [Abstract][Full Text] [Related]
7. Roles of Id1/HIF-1 and CDK5/HIF-1 in cell cycle reentry induced by amyloid-beta peptide in post-mitotic cortical neuron.
Chao AC; Chen CH; Wu MH; Hou BY; Yang DI
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118628. PubMed ID: 31884068
[TBL] [Abstract][Full Text] [Related]
8. [Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases].
Chen J; Wang ZF
Sheng Li Xue Bao; 2010 Aug; 62(4):295-308. PubMed ID: 20717630
[TBL] [Abstract][Full Text] [Related]
9. Study of ATM Phosphorylation by Cdk5 in Neuronal Cells.
She H; Mao Z
Methods Mol Biol; 2017; 1599():363-374. PubMed ID: 28477132
[TBL] [Abstract][Full Text] [Related]
10. Cdk5 activity in the brain - multiple paths of regulation.
Shah K; Lahiri DK
J Cell Sci; 2014 Jun; 127(Pt 11):2391-400. PubMed ID: 24879856
[TBL] [Abstract][Full Text] [Related]
11. A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases.
Batra S; Jahan S; Ashraf A; Alharby B; Jawaid T; Islam A; Hassan I
Int J Biol Macromol; 2023 Mar; 230():123259. PubMed ID: 36641018
[TBL] [Abstract][Full Text] [Related]
12. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
13. p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.
Li W; Allen ME; Rui Y; Ku L; Liu G; Bankston AN; Zheng JQ; Feng Y
J Neurosci; 2016 Nov; 36(44):11283-11294. PubMed ID: 27807169
[TBL] [Abstract][Full Text] [Related]
14. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.
Yousuf MA; Tan C; Torres-Altoro MI; Lu FM; Plautz E; Zhang S; Takahashi M; Hernandez A; Kernie SG; Plattner F; Bibb JA
J Neurochem; 2016 Jul; 138(2):317-27. PubMed ID: 26998748
[TBL] [Abstract][Full Text] [Related]
15. Synaptic deficits are rescued in the p25/Cdk5 model of neurodegeneration by the reduction of β-secretase (BACE1).
Giusti-Rodríguez P; Gao J; Gräff J; Rei D; Soda T; Tsai LH
J Neurosci; 2011 Nov; 31(44):15751-6. PubMed ID: 22049418
[TBL] [Abstract][Full Text] [Related]
16. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
Kesavapany S; Zheng YL; Amin N; Pant HC
Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
[TBL] [Abstract][Full Text] [Related]
17. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.
Binukumar BK; Pelech SL; Sutter C; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
J Alzheimers Dis; 2016 Sep; 54(2):525-33. PubMed ID: 27567857
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus.
Wei FY; Tomizawa K
Mini Rev Med Chem; 2007 Oct; 7(10):1070-4. PubMed ID: 17979810
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
[TBL] [Abstract][Full Text] [Related]
20. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
